drugset / Trial / NCT04217733
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
RandomizedParallel-groupTriple-blindTreatment
Summary
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome
Timeline
- Start
- 2019-11-01
- Primary completion
- 2030-12-01
- Completion
- 2030-12-30
Outcome
Met primary endpoint
paper Both groups 2 and 3 showed significant reductions in NRS scores when compared to the group 1. PMID 35221706 ↗
Publications
- El-Haggar SM, Hegazy SK, Abd-Elsalam SM, Elkaeed EB, Al-Karmalawy AA, Bahaa MM. A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial. J Inflamm Res. 2022 Feb 19;15:1159-1172. doi: 10.2147/JIR.S346608. eCollection 2022.
- El-Haggar SM, Hegazy SK, M Abd-Elsalam S, Bahaa MM. Open-label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to Irritable Bowel Syndrome. J Clin Pharm Ther. 2022 Mar;47(3):306-312. doi: 10.1111/jcpt.13556. Epub 2021 Nov 2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ethosuximide | Small molecule | 250 mg | — |
| Subject | Ethosuximide | Small molecule | 500 mg | — |
| Subject | Pentoxifylline | Small molecule | 400 mg | — |
| Comparator | Mebeverine | Small molecule | 135 mg | — |